A randomized controlled trial on the effect of Gushukang on bone mineral density in perimenopausal and postmenopausal women.

Researchers in China studied whether a traditional Chinese herbal medicine called Gushukang could help protect bone density in women going through menopause. The study included 142 women who were divided into three groups: one received standard hormone therapy, another took Gushukang herbal capsules, and the third received both treatments together. All participants were treated for six months, during which researchers measured their bone mineral density (BMD) and various hormone levels.

The results showed that both hormone therapy and Gushukang were effective at increasing bone density in menopausal women. However, the combination of hormone therapy plus Gushukang worked best, showing the most significant improvement in BMD after six months. Women taking only Gushukang saw bone density improvements without changes in their hormone levels, suggesting the herb works through a different mechanism than hormone replacement. Importantly, none of the treatments caused liver or kidney problems, indicating they were safe during the study period.

These findings suggest that Chinese herbal medicine may offer a valuable option for women concerned about bone loss during menopause, either alone or combined with conventional hormone therapy. This is particularly relevant for women who cannot or prefer not to use hormone therapy exclusively. While this study focused on herbal medicine rather than acupuncture specifically, many traditional Chinese medicine practitioners incorporate both modalities into treatment plans for menopausal symptoms and bone health. If you're considering Chinese medicine for bone health during menopause, seek a qualified practitioner licensed in traditional Chinese medicine or herbal medicine.

This randomized controlled trial evaluated Gushukang, a traditional Chinese herbal formula, for bone mineral density preservation in perimenopausal and postmenopausal women. 142 participants (median age 51-53 years) completed six months of treatment across three arms: hormone therapy (HT, n=49), Gushukang capsules (CM, n=42), or combination therapy (n=51). Baseline BMD ranged from 107.40-115.10 mg/cm³ across groups.

The combination therapy group demonstrated statistically significant BMD increases post-treatment (p<0.01), superior to either monotherapy. HT and combination groups showed expected hormonal changes (decreased FSH/LH, increased E2, p<0.05), while the CM group maintained stable hormone levels despite BMD improvements, suggesting a non-hormonal mechanism of action. No adverse effects on hepatic or renal function were observed in any group.

Clinical implications: Gushukang appears effective for BMD preservation in menopausal women and may offer synergistic benefits when combined with conventional HT, potentially allowing lower hormone doses while maintaining therapeutic efficacy.